ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Fundamental Analysis & Valuation

NASDAQ:ZYBT • KYG989MS1016

Current stock price

0.8793 USD
-0.03 (-3%)
At close:
0.8201 USD
-0.06 (-6.73%)
After Hours:

This ZYBT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ZYBT Profitability Analysis

1.1 Basic Checks

  • ZYBT had negative earnings in the past year.
  • In the past year ZYBT had a positive cash flow from operations.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -2.05%, ZYBT is in the better half of the industry, outperforming 75.52% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -3.46%, ZYBT is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROIC N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 5 10 15

1.3 Margins

  • ZYBT's Profit Margin has declined in the last couple of years.
  • ZYBT's Operating Margin has declined in the last couple of years.
  • ZYBT has a Gross Margin of 44.51%. This is in the better half of the industry: ZYBT outperforms 63.54% of its industry peers.
  • ZYBT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ZYBT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.51%
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ZYBT Health Analysis

2.1 Basic Checks

  • ZYBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ZYBT remains at a similar level compared to 1 year ago.
  • ZYBT has a better debt/assets ratio than last year.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • ZYBT has an Altman-Z score of 1.57. This is a bad value and indicates that ZYBT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ZYBT (1.57) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.02 indicates that ZYBT is not too dependend on debt financing.
  • ZYBT has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: ZYBT outperforms 55.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.57
ROIC/WACCN/A
WACC7.41%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • ZYBT has a Current Ratio of 1.49. This is a normal value and indicates that ZYBT is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.49, ZYBT is doing worse than 72.40% of the companies in the same industry.
  • ZYBT has a Quick Ratio of 1.10. This is a normal value and indicates that ZYBT is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of ZYBT (1.10) is worse than 75.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.1
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ZYBT Growth Analysis

3.1 Past

  • ZYBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -123.72%.
  • The Earnings Per Share has been growing by 528.02% on average over the past years. This is a very strong growth
  • Looking at the last year, ZYBT shows a very negative growth in Revenue. The Revenue has decreased by -18.89% in the last year.
  • Measured over the past years, ZYBT shows a very strong growth in Revenue. The Revenue has been growing by 854.79% on average per year.
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

Find the best growth stocksShow best growing peers

1

4. ZYBT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZYBT. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • ZYBT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ZYBT is cheaper than 78.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 25.48
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZYBT Dividend Analysis

5.1 Amount

  • ZYBT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYBT Fundamentals: All Metrics, Ratios and Statistics

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (4/2/2026, 8:02:36 PM)

After market: 0.8201 -0.06 (-6.73%)

0.8793

-0.03 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.49%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap41.67M
Revenue(TTM)248.68M
Net Income(TTM)-10.36M
AnalystsN/A
Price TargetN/A
Short Float %0.31%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP-1.59%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.16
P/FCF N/A
P/OCF 23.2
P/B 0.96
P/tB 1.04
EV/EBITDA 25.48
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY4.31%
SpS0.76
BVpS0.91
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.05%
ROE -3.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.51%
FCFM N/A
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.37
Cap/Depr 50.15%
Cap/Sales 5.07%
Interest Coverage N/A
Cash Conversion 97.56%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.1
Altman-Z 1.57
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.72%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-332.08%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.89%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-34.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.24%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A

ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZYBT.


What is the valuation status of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a valuation rating of 1 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Overvalued.


How profitable is ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 2 / 10.


Is the dividend of ZHENGYE BIOTECHNOLOGY HOLDIN sustainable?

The dividend rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 0 / 10 and the dividend payout ratio is -1.59%.